Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

act will break at that time.

Results from this multinational phase III study demonstrate that the combination of fludarabine, cyclophosphamide, and rituximab (FCR) provides a 10-month improvement in progression-free survival and a near doubling of complete response rates in patients with relapsed or refractory chronic lymphocytic leukemia.

A total of 552 patients from 17 countries with relapsed or refractory chronic lymphocytic leukemia were randomized to receive six 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with rituximab (FCR) (375 mg/m^2 rituximab intravenously at the start of first cycle and 500 mg/m^2 on day 1 for all subsequent cycles). Patients previously had received an average of one previous treatment regimen, including a single-agent alkylator therapy (66 percent), a purine-analog therapy (16 percent), or combination chemotherapy treatments (18 percent). The primary endpoint of the study was progression- free survival.

Patients in the FCR arm achieved a 30.6-month progression-free survival compared with 20.6 months in the FC arm, translating into a significant 10-month increase in progression-free survival for FCR combination therapy. The overall response rate was significantly higher in the FCR arm (70 percent) as compared with the FC arm (58 percent), because of superior complete-response rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall survival in the FC arm was reached at 53 months, it had not yet been reached in the FCR arm.

While Grade 3 and 4 adverse events were more prevalent in the FCR arm (80 percent) as compared with the FC arm (74 percent), serious adverse events were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR combination showed a favorable risk-benefit pr
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  DURECT Corporation (Nasdaq: DRRX ) ...  Total revenues were $4.4 million and net loss was $5.5 ... compared to total revenues of $4.6 million and net loss ... 2014.At June 30, 2015, we had cash and investments of ... at December 31, 2014.  At June 30, 2015, we had ...
(Date:8/3/2015)... Aug. 3, 2015  LEO Pharma supports the recent ... to include psoriasis as one of eight priority disease ... i .  Psoriasis is an autoimmune disease that has ... affecting 7.5 million people in the US alone. ii ... commitment to supporting patients living with psoriasis, LEO Pharma ...
(Date:8/3/2015)... , Aug. 3, 2015 OmniSeq, LLC ... Institute to the OmniSeq SM Genomic Network.  ... Cancer Institute (RPCI) and announced it was making ... a physician-driven, collaborative approach to genomic diagnostics that ... Cancer Institute is a rapidly expanding, multidisciplinary cancer ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... CHENGDU , Sichuan, China , ... TPI ) was invited by Sino American Biopharmaceutical,Association (SABPA) ... at, Irvine, California on April 24th, 2010 ... biotechnology industries, as well as,business opportunities to thrive in ...
... PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six ... American Association for Cancer Research,s (AACR) 101st Annual Meeting, held in ... , , ... cancer research, bringing together more than 17,000 attendees each year and covering ...
Cached Medicine Technology:Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association 2Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association 3PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 2PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 3
(Date:8/4/2015)... ... August 04, 2015 , ... Centurion Service Group, the world's largest medical ... used medical equipment. , The live auction will take place on Thursday, ... Lauderdale warehouse located at 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate ...
(Date:8/4/2015)... Orleans, LA (PRWEB) , ... August 04, 2015 ... ... Catholic institution of higher learning, announced today that its RN to BSN and ... programs have been awarded full accreditation through June 2020 from the Commission ...
(Date:8/4/2015)... ... August 04, 2015 , ... Please join us for the ... September 20th at Oneida Shores Park in Brewerton, NY. , Doris Connor was ... aneurysm at the young age of 59. Her family and friends have since become ...
(Date:8/4/2015)... ... , ... Following last month’s successful rollout of its client video series, ACE ... an Academic Setting, and The Importance of PVI Accreditation. , In The Benefits ... Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, Chandan ...
(Date:8/3/2015)... ... ... the pace of the economic recovery since the 2008 has been subject to much debate, ... the last six years. Unemployment has dropped from a 2009 high of 10 percent to ... in 2014, the U.S. stock market is at an all time high, and interest rates ...
Breaking Medicine News(10 mins):Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4
... events and experiences in both youth and middle adulthood ... according to a new supplemental issue of the Journals ... Furthermore, the authors find that the processes of aging linked ... simultaneously, as part of the same set of processes. ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- Older, ... leaner menopausal women, a small, new study suggests. The ... not taking medication for those symptoms. The women,s ... were also measured, and a special skin monitor and electronic ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- Smoking ... new study finds. Researchers used ultrasound to assess the ... in 1,893 women and 1,694 men in Finland, Sweden, the ... lifetime of smoking was associated with thickening of the arterial ...
... Reporter , WEDNESDAY, Aug. 31 (HealthDay News) -- Caring for ... be hard enough, but long-distance caregiving, which is becoming more ... added burdens. By 2012, an estimated 14 million Americans ... new names: "seagulls" and "pigeons." These terms refer to ...
... (HealthDay News) -- ,Hand axes, picks and other stone tools ... were using advanced tool-making methods at least 300,000 years earlier ... found in East Africa are believed to have been made ... who appeared about 2 million years ago and disappeared about ...
... in the late 1960s and early 1970s used marshmallows and ... gratification. If they held off on the temptation to eat ... of the children resisted, others didn,t. A newly published ... that these differences remain: Those better at delaying gratification as ...
Cached Medicine News:Health News:Being Heavier May Mean Fewer Hot Flashes for Women Over 60 2Health News:For Many Americans, Caregiving a Long-Distance Burden 2Health News:For Many Americans, Caregiving a Long-Distance Burden 3Health News:40-year follow-up on marshmallow test points to biological basis for delayed gratification 2
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: